mRNA Post-Transcriptional Enzymatic Capping Market Size, Share Detailed Report 2025 to 2034

Global mRNA Post-Transcriptional Enzymatic Capping Market Size is predicted to develop a 6.8% CAGR during the forecast period from 2025 to 2034.

mRNA Post-Transcriptional Enzymatic Capping Market Share & Trends Analysis Report, By Product Type (Capping Enzymes, Capping Kits, Reagents and Consumables, Custom mRNA Synthesis Services), By Application (mRNA Vaccines, mRNA Therapeutics, Research Tools, Emerging Applications), By End-User, By Region, and Segment Forecasts, 2025 to 2034

The process of adding a 5′ cap structure to messenger RNA (mRNA) via in vitro transcription (IVT) using enzymes such as RNA triphosphatase, guanylyltransferase, and methyltransferases is known as mRNA post-transcriptional enzymatic capping. The market encompasses post-transcriptional enzymatic capping performed using traditional enzymatic capping, optimized enzymatic systems, and advanced enzymatic systems. The latest optimized enzymatic systems (e.g., using Vaccinia virus capping enzymes) add Cap 0 or Cap 1 post-transcriptionally with an efficiency of 80-90%. These methods are more controlled than first-generation enzymatic methods, but they require multiple steps and purification, thereby increasing complexity.  

In eukaryotic cells, the mRNA capping process is crucial for enhancing mRNA stability, facilitating effective translation, and protecting the transcript from degradation. Enzymatic capping is carried out after transcription and achieves a capping efficiency of 80-100%, believed to provide better efficiency compared to co-transcriptional capping, which integrates cap analogues during transcription and may suffer from reduced efficiency due to GTP competition. It allows for the precise addition of cap-0 or cap-1 structures, which is particularly important for therapeutic mRNA applications to minimize innate immune responses. Furthermore, enzymatic capping is often patent-free and cost-effective, making it a suitable option for the large-scale manufacturing of therapeutic mRNAs without the use of viral or animal-derived materials. This approach has been successfully employed in the development of mRNA-based vaccines, such as those for COVID-19, ensuring stable, highly translatable, and low-immunogenicity mRNA products.

mRNA therapeutics, including vaccines and gene therapies, depend heavily on mRNA capping to ensure that the mRNA remains stable, efficiently translatable, and minimally immunogenic. This stability is crucial for allowing the mRNA to persist long enough in cells to produce therapeutic proteins, such as antigens in vaccines or functional proteins in genetic disorders.

Unlike co-transcriptional methods, which can yield heterogeneous cap structures, enzymatic capping provides precise control over the generation of cap-0 or cap-1 structures, which are crucial for optimizing mRNA function in therapeutic applications. As demand grows for individualized cancer vaccines and gene treatments, the need for flexible and highly accurate capping technologies is also increasing. The rapid expansion of mRNA-based therapies is driving the mRNA enzymatic post-transcriptional capping market, necessitating high-precision and high-efficiency capping. This requires substantial investments in infrastructure and research and development, as well as a shift toward outsourcing to specialized contract development and manufacturing organizations (CDMOs). However, the market must also navigate challenges related to cost, process scalability, and supply chain constraints.

Competitive Landscape

Some of the Major Key Players in the mRNA Post-Transcriptional Enzymatic Capping Market are:

• New England Biolabs (NEB)
• Takara Bio Inc.
• Canvax Biotech
• CELLSCRIPT
• Thermo Fisher Scientific
• Aldevron
• KACTUS
• Creative Biolabs
• Jena Bioscience
• Promega Corporation

Market Segmentation

The mRNA post-transcriptional enzymatic capping market is segmented into product type, application, and end-user. Based on product type, the market is segmented into capping enzymes, capping kits, reagents and consumables and custom mRNA synthesis services. Based on the application, the market is divided into mRNA vaccines, mRNA therapeutics, research tools, and emerging applications. Based on the end-user, the market is segmented into pharmaceutical and biotechnology companies, contract development and manufacturing organizations (CDMOs), academic and research institutes, and contract research organizations (CROs).

The Capping Enzymes Segment is Expected to Have the Highest Growth Rate During the Forecast Period

The capping enzymes segment is expected to have the highest growth rate during the forecast period and expected to hold the largest share in the mRNA post-transcriptional enzymatic capping market due to its central role in enabling precise, high-efficiency cap structure formation, a critical step in producing stable, functional, and low-immunogenicity mRNA for therapeutic applications. These enzymes, such as guanylyltransferase, RNA triphosphatase, and N7-methyltransferase, are indispensable for generating Cap-0 and Cap-1 structures, which are essential for mRNA stability, efficient translation, and immune evasion. As the demand for mRNA vaccines, personalized cancer immunotherapies, and gene therapies grows, so does the need for high-quality enzymatic capping processes that produce biologically active, regulatory-compliant mRNA.

The mRNA Vaccine Segment is estimated to Dominate the Market.

The largest application segment in the mRNA post-transcriptional enzymatic capping market is mRNA vaccines, particularly vaccine production. The COVID-19 pandemic significantly accelerated demand for mRNA vaccine manufacturing, and enzymatic capping is a crucial step in ensuring high translation efficiency and minimal immunogenicity, thereby further reinforcing vaccine applications as the dominant segment.

North America is expected to hold the Largest Market Share During the Forecast Period.

North America is expected to hold the largest share of the mRNA post-transcriptional enzymatic capping market, driven by its strong healthcare infrastructure and substantial public and private funding. The region benefits from a well-established biotechnology ecosystem, including the presence of major pharmaceutical and biotech companies at the forefront of mRNA innovation. Robust investment, comprising multiple billion-dollar initiatives, has further strengthened North America's leadership in expanding mRNA manufacturing and research capabilities. These efforts, combined with a favourable regulatory environment and access to cutting-edge technologies, have firmly positioned the region as a global hub for mRNA-based therapeutics and vaccine development.

Recent Developments:

• In August 2022, New England Biolabs (NEB®) revealed the Faustovirus Capping Enzyme (FCE). This mRNA capping solution supports the manufacturing needs of mRNA therapeutics by combining high activity and a wide temperature range. All of the enzymatic activity required to produce a Cap-0 structure, a crucial stage in the maturation of eukaryotic mRNA, is present in FCE, a single-subunit enzyme. In a one-pot procedure, users can produce a Cap-1 structure when combined with NEB's mRNA Cap 2´-O-Methyltransferase. The business added FCE, an enzyme found at NEB, to our line of mRNA synthesis products. This new product provides a simplified, scalable, and economical mRNA capping method for medicinal and research uses.

mRNA Post-Transcriptional Enzymatic Capping Market Report Scope: